Alfaro, Rosalie D.
HRN: 01-08-46 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/19/2024
CO-AMOXICLAV 625MG (TAB)
09/19/2024
09/26/2024
ORAL
625mg/tab
1 Tab Every 8 Hours
Herniated Nucleus Pulposus
Waiting Final Action
Indication: Empiric Type of Infection: Bone & Joint Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes